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Genemutations that lead to decreased contraction of vascular smooth-muscle cells (SMCs) can cause inherited thoracic aortic aneurysms
and dissections. Exome sequencing of distant relatives affected by thoracic aortic disease and subsequent Sanger sequencing of addi-
tional probands with familial thoracic aortic disease identified the same rare variant, PRKG1 c.530G>A (p.Arg177Gln), in four families.
This mutation segregated with aortic disease in these families with a combined two-point LOD score of 7.88. The majority of affected
individuals presented with acute aortic dissections (63%) at relatively young ages (mean 31 years, range 17–51 years). PRKG1 encodes
type I cGMP-dependent protein kinase (PKG-1), which is activated upon binding of cGMP and controls SMC relaxation. Although
the p.Arg177Gln alteration disrupts binding to the high-affinity cGMP binding site within the regulatory domain, the altered PKG-1
is constitutively active even in the absence of cGMP. The increased PKG-1 activity leads to decreased phosphorylation of the myosin
regulatory light chain in fibroblasts and is predicted to cause decreased contraction of vascular SMCs. Thus, identification of a gain-
of-function mutation in PRKG1 as a cause of thoracic aortic disease provides further evidence that proper SMC contractile function is
critical for maintaining the integrity of the thoracic aorta throughout a lifetime.Thoracic aortic aneurysms, which develop in the first part
of the aorta above the heart, can lead to life-threatening
acute aortic dissections if not properly managed. The
major risk factor for thoracic aortic diseases is uncon-
trolled hypertension, which is present in more than
70% of affected individuals.1 Thoracic aortic aneurysms
and dissections are familial in 20% of cases and can be in-
herited as a single-gene disorder in an autosomal-domi-
nant manner with variable expression and decreased
penetrance that is more pronounced in women.2 Muta-
tions causing inherited thoracic aortic aneurysms and dis-
sections have been identified in ACTA2 (actin, alpha 2,
smooth muscle, aorta [MIM 102620]), MYH11 (myosin,
heavy chain 11, smooth muscle [MIM 160745]), MYLK
(myosin light-chain kinase [MIM 600922]), TGFBR1
(transforming growth factor, beta receptor 1 [MIM
190181]), TGFBR2 (transforming growth factor, beta re-
ceptor II [70/80 kDa] [MIM 190182]), SMAD3 (SMAD
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that disruption of proteins involved in either smooth-
muscle cell (SMC) contraction or TGF-b signaling predis-
pose to thoracic aortic disease. For example, mutations
in the genes encoding a-actin and myosin heavy chain,
the two major proteins in the SMC contractile complex,
are predicted to disrupt the thin and thick filaments,
respectively, and thus decrease the ability of the SMCs
to contract in response to pulse pressures.4,5 SMC
contraction is initiated by an influx of Ca2þ, which binds
to and activates the calmodulin-dependent myosin light-
chain kinase, leading to phosphorylation of the regulato-
ry light chain (RLC [MIM 160781]) and, consequently,
activation of myosin ATPase to initiate movement of
the thin filaments along thick filaments. MYLK loss-of-
function mutations that are predicted to lead to
decreased RLC phosphorylation in vascular SMCs have
also been identified as a cause of inherited thoracic aortic
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To identify additional genes associated with inherited
predisposition to thoracic aortic aneurysms and dissec-
tions,11 we collected blood or saliva samples from affected
individuals and family members after obtaining proper
informed consent and approval at the University of Texas
Health Science Center at Houston or the Centre de Re´fe´r-
ence pour les Syndromes de Marfan et Apparente´s in
France. Exome sequencing was pursued with DNA from
two distantly related affected individuals (coefficient
of relationship ¼ 1/8) from a large family, TAA216,
with autosomal-dominant inheritance of a predisposi-
tion to thoracic aortic disease as previously reported
(dbGaP accession number of exome-sequencing data:
phs000347.v1.p1).7 No mutation in known genes associ-
ated with familial thoracic aortic diseases was identified
in this family. The phenotype in the family has been re-
ported previously and is notable for aortic dissections in
both men and women as young as 17 years of age.12
Gene variants identified by whole-exome sequencing
were filtered, and only rare variants shared by the two
affected relatives and not present in internal control
exomes were pursued, as previously described.8 The vari-
ants meeting these criteria were assessed for segregation
with aortic disease in TAA216, decreasing the number of
candidate rare variants down to four missense variants,
one nonsense variant, and one frameshift variant
(Figure 1A and Table S1, available online). One of the
genes, PRKG1, encodes type I cGMP-dependent protein ki-
nase (PKG-1 [RefSeq accession number NM_001098512.2;
MIM 176894]), which controls SMC relaxation, and was
therefore an excellent candidate gene for thoracic aortic
disease. Analysis of additional exome data from 55 unre-
lated probands identified the same variant, PRKG1
c.530G>A (p.Arg177Gln), in the probands of families
TAA508 and TAA690, but no other rare variants were found
in this gene. Sanger sequencing of PRKG1 in 307 affected
probands identified the same variant in another family,
TAA292. DNA sequencing of family members in these
three additional families confirmed segregation of the
PRKG1 variant with thoracic aortic disease (Figure 1A).
Two-point linkage analysis of thoracic aortic disease with
the PRKG1 variant resulting in p.Arg177Gln in these four
families was performed with Superlink software and re-
vealed a combined LOD score of 7.88.13 The Arg177 amino
acid is highly conserved, and the p.Arg177Gln variant is
absent from 8,600 European American chromosomes and
4,400 African American chromosomes in the National
Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project Exome Variant Server (Figure 1B). Six
HapMap SNPs flanking the PRKG1 c.530G>A variant
were assessed in these families, which showed that
TAA508 and TAA690 share a common haplotype in this re-
gion, but this haplotype differs from the mutation-associ-
ated haplotype in TAA216 and TAA292 (Table S2). Sanger
sequencing of PRKG1 also identified two variants,
c.1997G>C (p.Gly666Ala) and c.1421A>T (p.Tyr474Phe),
in families TAA165 and TAA561, respectively (Figure S1).The AmerGly666 is conserved, and the p.Gly666Ala variant is pre-
dicted to be probably damaging by PolyPhen-2 analysis;
however, TAA165 does not have enough affected family
members to establish that this variant segregates with
disease in the family. Tyr474 is conserved, but the
p.Tyr474Phe variant is predicted to be benign and does
not segregate with aortic disease in TAA561. Therefore,
although other rare variants in PRKG1 have been identified
in individuals with familial thoracic aortic diseases and are
present in the general population (Figure 1C), only the
PRKG1mutation resulting in p.Arg177Gln has been shown
to cause thoracic aortic disease.
Individuals with the p.Arg177Gln alteration presented
with either thoracic aortic dissection or mild to severe
aortic root dilatation (Table S3). Thoracic aortic disease
was fully penetrant in family members over 18 years of
age. Of the 31 mutation-positive individuals and affected
relatives, including five who must have carried the muta-
tion on the basis of their position in the pedigree and six
who were at a 50% risk of inheriting the mutation, the
majority (63%) presented with acute aortic dissections
(Stanford type A, n ¼ 11; type B, n ¼ 6; unspecified,
n¼ 2) and 37% had aortic root enlargement; one died sud-
denly of an unknown cause. Acute aortic dissections
occurred as young as 17 years of age andwere equally pene-
trant in men and women. There was no gender difference
in the age of onset of dissections (women: mean age 31
years, range 17–45 years; men: mean age 31 years, range
18–51 years). Women with the p.Arg177Gln alteration pre-
sented with dissections at a significantly younger age than
they did with aortic root dilatation (31 years for dissec-
tions, 43 years for aortic dilatation, p ¼ 0.009, n ¼ 19),
whereas men did not (31 years for dissection, 39 years for
aortic dilatation, p ¼ 0.18, n ¼ 11). Aortic measurements
were available for two individuals who had type A dissec-
tions: TAA216 IV:3 had a 5.7 cm aortic root prior to dissec-
tion, and TAA690 III:3 had a 3.7 cm aortic root and 4.3 cm
ascending aorta at the time of dissection. There were fam-
ily members with mild to severe aortic root dilatation, and
the largest aortic diameter was noted to be 5.7 cm. The
medical records were reviewed for additional risk factors
of aortic dissection, specifically pregnancy and hyperten-
sion. Of the 19 individuals who had dissections, five had
a diagnosis of hypertension and five had evidence of
end-organ damage associated with hypertension, specif-
ically mild to moderate left ventricular hypertrophy or
chronic small-vessel cerebrovascular disease at the time
of presentation with aortic dissection; ten individuals
had insufficient information in their medical records.
Two women, TAA508 III:1 and TAA690 III:1, had dissec-
tions in the postpartum period and in the third trimester
of pregnancy, respectively.
Records were reviewed for additional vascular disease,
and some individuals were noted to have enlargement of
the descending thoracic aorta, abdominal aorta, and other
arteries. In family TAA508, individual II:3 had a giant cor-
onary artery aneurysm treated with covered stent andican Journal of Human Genetics 93, 398–404, August 8, 2013 399
Figure 1. Identification of PRKG1 c.530G>A (p. Arg177Gln) as the Mutation Responsible for Thoracic Aortic Disease in Families
TAA216, TAA292, TAA508, and TAA690
(A) Family pedigrees. The legend indicates the disease and mutation status of the family members. The age at diagnosis of aortic aneu-
rysm or dissection (‘‘dx’’) and age at death (‘‘d’’) are shown in years. A diagonal line across a symbol indicates that an individual is
deceased, an arrow indicates a proband, and a single asterisk indicates an individual whose DNA was used for exome sequencing. Mu-
tation-positive children who are unaffected and two adults who have an unknown disease status are not included in the pedigrees.
(B) Ortholog conservation of PKG-1 variants identified in individuals with thoracic aortic disease and surrounding amino acids.
(C) Schematic representation of PRKG1. The boxes represent exons 1–18, and the UTRs and the open reading frame are designated. The
PRKG1 rare variants identified in this study are on the top of the gene diagram, and the rare variants identified in European Americans in
the NHLBI Exome Variant Server are indicated below. Bold type designates variants predicted to be possibly or probably damaging by
PolyPhen-2 analysis, and regular type designates variants predicted to be benign.individual II:1 had a spontaneous coronary artery dissec-
tion and ectatic coronary arteries. Three individuals
(TAA216 III:3 and III:9 and TAA292 III:1) were noted to
have tortuosity of the thoracic aorta. None of the individ-400 The American Journal of Human Genetics 93, 398–404, August 8uals with the mutation and examined by a clinical geneti-
cist had features of Marfan syndrome (MIM 154700) or any
other genetic syndrome associated with thoracic aortic
disease., 2013
Figure 2. Effect of PKG-1a p.Arg177Gln
on cGMP Binding and Kinase Activity
(A) Structural model of the CNB-A domain
of PKG-1a. The crystal structure of the
PKG-1b (92–227):cGMP complex (Protein
Data Bank ID 3OD0) was used for
modeling the CNB-A domain of PKG-1a
because PKG-1a and PKG-1b have the
same protein sequence at this region and
this is the only structure available for
CNB-A with bound cGMP. The phos-
phate-binding cassette (PBC) is colored in
yellow, the aB helix is in red, and the rest
is in cyan. cGMP is colored by atom type
with white and black carbons. The second-
ary-structure elements and both termini
are labeled. In the right panel, a zoomed-
in view shows the region around Arg177
(corresponding to Arg192 in PKG-1b).
Arg177 not only binds the cyclic phos-
phate of cGMP but also stabilizes the PBC
by interactingwith Leu139 (corresponding
to Leu154 in PKG-1b) at strand b5 and
Gly167 (corresponding to Gly181 in
PKG-1b) at the base of PBC.
(B) Direct fluorescence-polarization assay
using 8-Fluo-cGMP. PKG-1a amino acids
79–212 and p.Arg177Gln PKG-1a were
cloned into pQTEV, and both protein frag-
ments were purified from E. coli Dcya
TP2000, which lacks adenylyl cyclase
activity.17 The proteins were purified as
described previously.16 The direct fluores-
cence-polarization assay was performed
according to the procedure described by
Moll.18
(C) Kinase activities of wild-type (‘‘WT’’)
and altered (‘‘ALT’’) proteins, as well as of
a 1:1 mixture of wild-type and altered pep-
tides, were assayed with 35 ng protein in
reactions containing 8 mg kemptide. Flag-
tagged wild-type and altered PKG-1a
proteins were purified from transfected
HEK293T cells with the use of anti-Flag M2 agarose (Sigma-Aldrich). Reactions were performed for 5 min at 30C in 40 mM HEPES
(pH 7.0), 8 mg kemptide (Sigma-Aldrich), 10 mM MgCl2, 60 mM ATP, 0.6 mCi 32P-g-ATP, and variable amounts of cGMP. Reactions
were stopped by spotting on P81 phosphocellulose paper, and activity was measured by liquid scintillation counting. The results
show that p.Arg177Gln led to constitutive activation of kinase when assayed alone and increased activity of the kinase when purified
with the wild-type protein. Assays were performed in triplicate.
(D) Fibroblasts explanted from individuals TAA216 III:10 and III:21 and age-matched control fibroblasts were exposed to variable doses
of 8-Br-cGMP. The methods of fibroblast cell culture and 8-Br-cGMP treatment followed the procedures previously described.19,20 RLC
phosphorylation was lower in the mutant fibroblasts when exposed to 8-Br-cGMP than in control fibroblasts (left panel). On the x axis,
the percentage of pRLC is based on the pRLC level in each sample over the pRLC level averaged from the two control fibroblast lines in
the absence of 8-Br-cGMP (right panel). The concentration unit of 8-Br-cGMP is mM, and assays were performed in triplicate.Although two PKG-1 splice variants (PKG-1a and PKG-
1b) exist in mammalian tissues, PKG-1a is the major iso-
form present in vascular SMCs.14 PKG-1a is a homodimer
with the N-terminal regulatory (R) and C-terminal catalytic
(C) domains. The R domain consists of a leucine zipper
motif that is involved in kinase dimerization and cellular
localization, an autoinhibitory sequence that binds the
active site of the C domain in the absence of cGMP, and
tandem cGMP binding domains (CNB-A and CNB-B) that
bind cGMP and activate the kinase. Upon binding of
cGMP to CNB-A and CNB-B, the R domain undergoes ma-
jor conformational change—releasing and activating the C
domain.15 Arg177 is located in CNB-A, which binds cGMPThe Amerwith nanomolar affinity. PKG-1a and PKG-1b have the
same CNB-A domain, and the PKG-1b (amino acids 92–
227)-cGMP complex is the only structure available for
CNB-A with bound cGMP.16 In the crystal structure of
the PKG-1b (92–227)-cGMP complex, Arg192, which cor-
responds to Arg177 in PKG-1a, interacts directly with the
cyclic phosphate moiety and is essential for cGMP binding
(Figure 2A).16 A p.Arg177Gln alteration would substitute
the guanidinium side chain with a carboxamide, which
would disable its interaction with the cyclic phosphate.
To confirm decreased cGMP binding, we purified the
altered and wild-type CNB-A of PKG-1a (residues 79–212)
and used a fluorescence polarization assay to measure theican Journal of Human Genetics 93, 398–404, August 8, 2013 401
Table 1. Kinase-Activity Assays of Wild-Type and Altered PKG-1a
cGMP (nM) WT Alt WT/Alt Mixeda WT/Altb WT/Altc
0 0.11 1.4 0.53 0.76 0.43
1 0.15 1.36 0.55 0.76 0.45
10 0.21 1.35 0.68 0.78 0.5
30 0.41 1.31 0.8 0.86 0.64
100 1.04 1.35 1.21 1.2 1.12
300 1.47 1.48 1.4 1.48 1.47
1,000 1.59 1.56 1.5 1.58 1.58
3,000 1.49 1.49 1.5 1.49 1.49
10,000 1.51 1.51 1.48 1.51 1.51
aPKG-1a activity observed in cells that were transfected with equal amounts of
altered and wild-type constructs to mimic the heterozygous PRKG1 mutations
identified in thoracic aortic disease.
bHypothetical kinase activity of the mixed sample was calculated under the
assumption that the wild-type and altered proteins act independently (0.5
[WT] þ 0.5 [Alt]).
cHypothetical kinase activity of the mixed sample was calculated under the
assumption that the wild-type completely inhibits the altered protein in heter-
odimers (0.5 [WT] þ 0.25 [WT þ Alt]).binding affinity to 8-Fluo-cGMP (Figure 2B). The half
maximal effective concentration (EC50) for the altered
CNB-A was more than 32,000-fold lower than the wild-
type, indicating that p.Arg177Gln results in a CNB-A that
does not bind or respond to cGMP.
To test the effect of the p.Arg177Gln alteration on full-
length PKG-1a, we purified altered and wild-type PKG-1a
in human embryonic kidney 293T (HEK293T) cells and
measured phosphotransferase activity. Interestingly, the
measurements indicated that p.Arg177Gln PKG-1a was
highly active even without cGMP, whereas wild-type
PKG-1a required cGMP for activation (Figure 2C). When
equal amounts of the altered and wild-type PKG-1a con-
structs were cotransfected into HEK293T cells to mimic
the heterozygous mutation identified in affected individ-
uals, kinase activity was higher both at baseline and
with cGMP exposure than that of wild-type PKG-1a
(Figure 2C). The activity in the mixed samples was lower
than expected if the wild-type and altered peptides were
acting independently of each other but higher than ex-
pected if the wild-type was completely inhibiting the
altered protein in heterodimeric complexes (Table 1). The
kinase assays of p.Gly666Ala PKG-1a showed activity
levels similar to those of the wild-type, providing further
evidence that this variant does not cause thoracic aortic
disease (Figure S2). Taken together, these results suggest
that the p.Arg177Gln alteration structurally perturbs
PKG-1a and thus abolishes the ability of the R domain to
inhibit kinase activity in the absence of cGMP and results
in a kinase whose activity is no longermodulated by cGMP.
PKG-1a is activated in SMCs when nitric oxide stimu-
lates soluble guanylyl cyclase to increase cellular cGMP
levels. The activated PKG-1a regulates many cellular sys-
tems that lead to relaxation of SMCs, including phosphor-402 The American Journal of Human Genetics 93, 398–404, August 8ylation of the regulatory myosin-binding subunit (MYPT)
of the phosphatase that dephosphorylates RLC. MYPT1 is
specifically phosphorylated by PKG-1a at Ser695, which
leads to enhanced phosphatase activity and increased
dephosphorylation of the RLC. Thus, the increased kinase
activity associated with the PKG-1a p.Arg177Gln alter-
ation should lead to decreased levels of phosphorylated
RLC (pRLC). Fibroblasts explanted from two individuals
with the PKG-1a Arg177Gln alteration and matched con-
trol fibroblasts were exposed to variable doses of 8-Fluo-
cGMP. The levels of pRLC were slightly lower in the
mutant cells than in the control cells, and the reduced
pRLC levels in the mutant fibroblasts were more pro-
nounced with exposure to low doses of 8-Fluo-cGMP
(Figure 2D).
Given thatMYLK and PRKG1mutations are predicted to
decrease aortic SMC contraction as a result of decreased
phosphorylation and increased dephosphorylation of the
RLC, respectively, we expected similar pathological fea-
tures in the aortas of individuals with mutations in these
genes. Aortic tissues from two individuals (TAA216 III:10
and TAA292 II:4) with the PRKG1 mutation demonstrated
the typical pathology associated with thoracic aortic dis-
ease: increased proteoglycan accumulation, decreased
SMCs, and elastic fiber loss and fragmentation (Figure 3).
These aortas showed a substantial increase in the small
arteries in the medial layer from the vasa vasorum
of the aortas from PRKG1-mutation-positive individuals
compared to controls (Figure 3). Interestingly, similar inva-
sion of the vasa vasorum into the medial layer was previ-
ously observed in aortas of individuals with MYH11 and
MYLK mutations.6,21
The data presented here demonstrate that a single
missense mutation in PRKG1 leads to thoracic aortic dis-
ease. Although rare variants in PRKG1 are present in the
population, only the p.Arg177Gln alteration was
confirmed to be disease causing, most likely as a result of
its unique gain-of-function effect on PKG-1a activity.
Therefore, only PRKG1 rare variants that were demon-
strated to increase PKG-1a activity should be considered
disease causing until further data are available. Similar to
previously identified mutations in genes encoding pro-
teins involved in SMC contraction, PRKG1 c.530G>A leads
to PKG-1a alteration p.Arg177Gln, which increases PKG-
1a activity and causes decreased phosphorylation of the
RLC and thus should decrease vascular SMCs contraction.
The mechanism for the increased activation of the altered
protein and how the altered protein partially disrupts the
regulation of the wild-type protein should be the focus of
future studies. Additionally, the PKG-1a p.Arg177Gln alter-
ation should lead to SMC relaxation and hypotension on
the basis of the biochemical analysis, and additional
studies are needed for determining why hypertension is
present in many individuals who have the mutation.
Finally, these data illustrate the complexity of associating
rare variants with complex, adult-onset diseases. Studies
testing the association between rare variants in PRKG1, 2013
Figure 3. Aortic Pathology from Individ-
uals TAA216 III:10 and TAA292 II:4, with
the PRKG1 Mutation Resulting in
p.Arg177Gln, and an Unaffected Control
Compared with the control aorta, aortas
from cases showed medial degeneration
upon Movat staining, as shown by
increased proteoglycan deposition (blue),
elastic-fiber fragmentation and loss
(black), and decreased cells (red). Immuno-
staining for Von Willebrand factor (vWF,
marker of endothelial cells; brown)
showed increased vascularity (arrows) in
the medial layer of aortas from individuals
with the PRKG1 mutation. In the control
aortas, only the vasa vasorum in the
adventitial layer or at the boundary
(arrowhead) of the medial and adventitial
layers stained with vWF. Note that the
aortic specimen from TAA292 II:4 is from
a dissected segment of the aorta and the
images only show the medial layer of
aorta.and thoracic aortic disease by using burden tests would not
demonstrate an association, and studies with the specific
PRKG1 mutation resulting in p.Arg177Gln would only
show an association in a large cohort of affected individ-
uals or if family-based studies were pursued.Supplemental Data
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